Advertisement

SCLC

(Small Cell Lung Cancer)

Relevant Articles About Non Small Cell Lung Cancer Research and Clinical Trials

Stories to Watch

VIEW ALL

Advertisement

OncWeekly Featured Trials

SCLC (Small Cell Lung Cancer)AmrubicinIfinatamab deruxtecanLurbinectedinTopotecanRecruitingAustraliaAustriaBelgiumBrazilCanadaChinaCzechiaFranceGermanyGreeceHungaryItalyJapanKorea, Republic ofNetherlandsPolandPortugalRomaniaSpainSwitzerlandTaiwanTurkeyUnited KingdomUnited States 8NCT06203210Phase 3IDeate-Lung02
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician’s Choice in Subjects With Relapsed Small Cell Lung Cancer

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician’s Choice in Subjects With Relapsed Small Cell Lung Cancer

SCLC (Small Cell Lung Cancer)DurvalumabOther: PlaceboTremelimumabActiveNot Yet RecruitingArgentinaBelgiumCanadaChinaCzechiaGermanyIndiaItalyJapanKorea, Republic ofNetherlandsPolandRussian FederationSpainTaiwanTurkeyUnited KingdomUnited StatesVietnam 9NCT03703297Phase 3ADRIATIC
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NSCLC (Non-Small Cell Lung Cancer)Other CancersSCLC (Small Cell Lung Cancer)(vic-)trastuzumab duocarmazineRecruitingUnited States 0NCT02146170
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Advertisement

Advertisement

LATEST

Advertisement

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy

VIEW ALL

SELECT ONCOLOGY JOURNAL ARTICLES

Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma

Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma

Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …

1222 Antigen-specific delivery of TCR and costimulatory signals by a protein scaffold selectively activates and markedly expands naïve MART-1-specific CD8+ T cells

1222 Antigen-specific delivery of TCR and costimulatory signals by a protein scaffold selectively activates and markedly expands naïve MART-1-specific CD8+ T cells

Background Adoptive cell transfer (ACT) shows promise as an immunotherapy for melanoma and other cancers. However, there are several challenges associated with ACT such as the logistical complexity and inconsistency when using patient-derived antigen-presenting cells for …

890 Nivolumab plus ipilimumab in anti-PD(L)-1 naïve and experienced HCC patients -- single institute experience in Taiwan

890 Nivolumab plus ipilimumab in anti-PD(L)-1 naïve and experienced HCC patients -- single institute experience in Taiwan

Background Immune checkpoint inhibitors (ICIs) are standard therapy for advanced hepatocellular carcinoma (HCC). However, the efficacy of combining nivolumab and ipilimumab in Anti-PD(L)-1 Naïve and Experienced HCC patients remains unclear. Methods We retrospectively reviewed 23 patients with advanced …